Due: October 4, 2024
The intent of the Psychedelic Treatment Research Clinical Trial Award is to support clinical trials with eligible U.S. Service Members to evaluate treatments for post-traumatic stress disorder (PTSD) and/or traumatic brain injury (TBI) involving the use of covered psychedelic substances. Treatment may involve the use of covered psychedelic substances alone or in conjunction with other evidence-based treatments. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.